Clalit Health Services

IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries

Retrieved on: 
Friday, April 5, 2024
HMO, Pressure, Patient, Food and Drug Administration, Health care, Safety, Interim, Clalit Health Services, FDA, Health, Food

PressureSafe™ uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries with real-time analysis at the point of care.

Key Points: 
  • PressureSafe™ uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries with real-time analysis at the point of care.
  • In the U.S. alone, 60,000 patients die every year as a direct result of pressure injuries.
  • Patient care cost per pressure injury ranges from $20,900 up to $151,700, for the 2.5 million patients per year who develop pressure injuries.
  • Pressure injuries are one of the five most common harms experienced by patients and the second most common claim for lawsuits after wrongful death.

Nanox and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest Diseases

Retrieved on: 
Thursday, February 29, 2024
Clalit Health Services, Medical imaging, ARC, 3D, Radiology, X-ray, Lung, Radiation, LTD, Risk, Beilinson, Rabin Medical Center, Patient, Trial of the century, CAC, Partnership

PETAH TIKVA, Israel, Feb. 29, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and Beilinson Hospital, a leading Israeli hospital and part of Rabin Medical Center, owned and operated by Israel’s largest healthcare organization, Clalit Health Services, today announced their collaboration to conduct a clinical study evaluating the Nanox.ARC 3D imaging system in a clinical outpatient setting at Beilinson Hospital. The study will specifically assess the diagnostic capabilities of the Nanox.ARC’s tomographic imaging system compared with conventional two-dimensional radiography for detection of lung and chest disease in adults. Such a study may help determine the clinical utility of the additional information provided by the 3D tomographic imaging, potentially preventing the need for more advanced imaging and exposure to additional radiation.

Key Points: 
  • The study will specifically assess the diagnostic capabilities of the Nanox.ARC’s tomographic imaging system compared with conventional two-dimensional radiography for detection of lung and chest disease in adults.
  • The study is being led by Professor Eli Atar, M.D., FSIR, Director of the Department of Imaging, and Dr. Ahuva Grubstein, M.D., Department of Diagnostic Radiology, both at Beilinson Hospital.
  • This study evaluating the Nanox.ARC is an addition to the existing collaboration between Nanox AI and Clalit, and the second study conducted with Beilinson Hospital.
  • “This technology shows promise to expand clinicians’ capabilities for more precise readings and earlier detection across a range of pulmonary conditions.

IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries

Retrieved on: 
Tuesday, February 20, 2024
PHD, Incidence, HMO, Principal, Inflammation, Pressure, Calibration, Infrared, Skin, Methodism, Standard of care, Conference, Safety, Nursing, Biomarker, Rabin Medical Center, Patient, Clalit Health Services, CSO, Diagnosis, Trial of the century, Medical device

The objective of the study was to evaluate the sensitivity, specificity, and usability of PressureSafe to detect early-stage pressure injuries Stage 1 / suspected deep tissue injuries (sDTI) before skin breakage, compared to standard of care.

Key Points: 
  • The objective of the study was to evaluate the sensitivity, specificity, and usability of PressureSafe to detect early-stage pressure injuries Stage 1 / suspected deep tissue injuries (sDTI) before skin breakage, compared to standard of care.
  • PressureSafe detected biomarkers and changes in tissue structures under the skin’s surface as they relate to pressure injuries.
  • The 14-day efficacy portion of the single arm, bi-center study evaluated 38 patients at high risk of pressure injury development.
  • Based on these data, the study concluded that PressureSafe is a safe, efficient, and valuable method for early detection of pressure injuries.

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

Retrieved on: 
Tuesday, February 13, 2024
Hospital, HMO, Health, Infrared, Trial of the century, Principal investigator, Death, Conference, Safety, Rabin Medical Center, Patient, Clalit Health Services, Medical device

The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe ™ , IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection.

Key Points: 
  • The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe ™ , IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection.
  • IR-MED’s clinical and execute team will demonstrate PressureSafe at booth #102 at NPIAP 2024, which is attended by the world’s top thought leaders and practitioners in the prevention and treatment of pressure injuries.
  • Pressure injuries cost the U.S. healthcare system $26.8 billion and lead to 60,000 deaths annually.
  • PressureSafe was found to be over 90% accurate in detecting pressure injuries based on interim results from a multicenter study.

XRHealth Deploys Hundreds of VR Headsets in Israel for Victims of Hamas Attacks, Assisting Patients Coping with Anxiety, Stress, and PTSD

Retrieved on: 
Thursday, October 19, 2023
VR, Hamas, Survivor, Nursing home, Aurora Mental Health & Recovery, Distribution, Assisted living, Nursing, Live, PTSD, Hospital, Meditation, Anxiety, Patient, Clalit Health Services, Mental health

BOSTON, Oct. 19, 2023 /PRNewswire/ -- XRHealth, the leading healthcare platform in Spatial computing, announces today that they are currently deploying hundreds of VR headsets in Israel to treat patients coping with anxiety, stress, and PTSD as a result of the recent Hamas attacks. The distribution of the headsets will span across 30 hospitals, nursing homes, assisted living facilities and mental health centers throughout Israel (including three Clalit hospitals).

Key Points: 
  • The distribution of the headsets will span across 30 hospitals, nursing homes, assisted living facilities and mental health centers throughout Israel (including three Clalit hospitals).
  • Just 48-hours after the attacks, XRHealth mobilized to deliver the headsets to Israel to assist with the treatment and recovery of patients.
  • XRHealth provides VR/AR therapy to patients suffering from both mental and physical conditions and can treat patients from the comfort of their home or at a healthcare facility.
  • Anyone interested in donating headsets to Israel, please contact XRHealth at [email protected] .

Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs

Retrieved on: 
Thursday, September 28, 2023
Clalit Health Services, Insurance, CE, Fatty liver disease, CT, Radiation, European Heart Journal: Cardiovascular Imaging, Osteoporosis, Rabin Medical Center, Cardiovascular disease, HMO, CT scan, Trial of the century, Radiology, CAC, Patient, Physician, Non-alcoholic fatty liver disease, Mortality, FDA, LTD, Artifact, Disease, Medical device, Medical imaging

NEVE ILAN, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that HealthCCSng, an AI-powered solution created by Nanox’s deep-learning medical imaging analytics subsidiary, Nanox.AI, was used in a clinical study evaluating routine CT scans and found that 58% of patients unknowingly had moderate to severe levels of coronary artery calcium (CAC), a proven indicator of future cardiac events. The study was sponsored by Nanox.AI and conducted by the Beilinson Hospital, one of the largest and most renowned multidisciplinary medical institutions in Israel, and utilized Nanox.AI’s HealthCCSng, an FDA-cleared and CE marked tool designed specifically for cardiac health assessment.

Key Points: 
  • Nanox.AI’s HealthCCSng solution utilizes medical imaging data from routine chest CT scans to automatically quantify and analyze CAC category.
  • CAC is the strongest predictor of future cardiac events, with patients in the highest category being over 20 times more likely to suffer a cardiac event.
  • “The patients in this study received routine CT scans that had nothing to do with a cardiac concern.
  • HealthCCSng supports clinicians in diagnosing patients with cardiovascular disease who were previously undetected, while stratifying such patients so that they can obtain the appropriate preventative cardiac care and treatment.

IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024

Retrieved on: 
Tuesday, September 26, 2023
Dark, Clalit Health Services, Prevalence, Efficacy, HMO, Biomarker, Person, Nursing, Clinical trial, Hospital, Health care, Patient, Physician, Pressure, AI, Mortality, Research, Economics, Medical device, Health insurance, Skin

With a network of 85 hospitals, 9 of which are acute care facilities, Methodist Healthcare employs more than 11,000 people, including 2,700 physicians.

Key Points: 
  • With a network of 85 hospitals, 9 of which are acute care facilities, Methodist Healthcare employs more than 11,000 people, including 2,700 physicians.
  • While early stage pressure injuries can be more difficult to see on dark skin tones, the current standard of care for the detection of pressure injuries is visual skin inspection.
  • The study has been submitted to Methodist’s Institutional Review Board for approval,” commented Dr. Yaniv Cohen, IR-MED’s Co-Founder and Chief Science Officer.
  • IR-MED’s prior usability study for PressureSafe was conducted at two hospitals in Israel owned by Clalit, the world’s second largest health maintenance organization (HMO).

Israel's largest healthcare provider to use Sectra's digital pathology solution for improved cancer diagnostics

Retrieved on: 
Thursday, September 7, 2023
Clalit Health Services, International, Marie Cassidy, Pathology, Cancer, Microsoft, Research, KLAS, VNA, Health care, Diagnosis, Azure, Medical imaging, Sectra AB

LINKÖPING, Sweden, Sept. 7, 2023 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) solution for digital pathology will be utilized by Israel's largest healthcare provider—Clalit Health Services.

Key Points: 
  • LINKÖPING, Sweden, Sept. 7, 2023 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra's (STO: SECT B) solution for digital pathology will be utilized by Israel's largest healthcare provider—Clalit Health Services.
  • It aims to simplify the work of Clalit's pathologists in reviewing and collaborating on cases, leading to more precise cancer diagnostics.
  • "We are looking forward to implement Sectra's digital pathology solution," says Dr. Orly Weinstein, Deputy Director General, Head of Hospital Division, Clalit Health Services.
  • The contract, signed in August 2023, includes Sectra's digital pathology solution and cloud-based storage service using Microsoft Azure.

IR-MED’s AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care

Retrieved on: 
Monday, July 17, 2023
Clalit Health Services, Pressure, Interim, Health, Bed, Eye, HMO, Rabin Medical Center, Biomarker, Trial of the century, Wheelchair, U.S. FDA, Ischemia, Patient, FDA, Skin, Safety, Medical imaging, Petah Tikva

PressureSafe demonstrated very high efficacy in noninvasively detecting the presence and absence of pressure injuries below the skin’s surface.

Key Points: 
  • PressureSafe demonstrated very high efficacy in noninvasively detecting the presence and absence of pressure injuries below the skin’s surface.
  • Pressure injuries can occur when a patient must stay in a wheelchair or bed and isn’t able to move.
  • Currently, visual inspection is used to detect and classify pressure injuries according to depth, width, degree of tissue loss, and presence of granulated tissue.
  • $26.8 billion is spent each year to prevent and treat pressure injuries that result from long-term pressure on hard surfaces such as wheelchairs and beds.

Study: TytoCare Home Smart Clinic Reduces Total Cost of Care by 7% for Health Plan Members

Retrieved on: 
Wednesday, July 12, 2023
Stanford University, Wheeze, Tyto, Trust, Journal, Patient, Journal of Health Economics, Diagnosis, FDA, Medical device, Nursing, Clalit Health Services, Tel Aviv University

The researchers found that the Home Smart Clinic led to a 12% increase in primary care utilization, 24.1% reduction in emergency room utilization, and an 11.3% reduction in urgent care utilization.

Key Points: 
  • The researchers found that the Home Smart Clinic led to a 12% increase in primary care utilization, 24.1% reduction in emergency room utilization, and an 11.3% reduction in urgent care utilization.
  • By directing patients to the right care to meet their needs, TytoCare utilization led to a 7% reduction in cost of care across all age groups, and a 9% reduction among adults.
  • The TytoCare Home Smart Clinic is the only all-in-one device on the market that can replicate the doctor’s office in the home.
  • Recently, TytoCare announced FDA approval for its AI-backed Tyto Insights™ for Wheeze Detection feature, enabling accurate remote diagnosis of wheezing via the Home Smart Clinic.